Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics using generative AI, has announced an underwritten public offering of $50 million worth of its common stock. The company plans to give underwriters a 30-day option to purchase an additional $7.5 million in shares. The proceeds from this offering will be used to advance Absci's internally developed programs, invest in its Integrated Drug Creation™ platform, and for general corporate purposes. The offering is being managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities $(USA)$ LLC, and is subject to market and other conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。